Virbac


Making good strides

01/10/24 -"Considering the robust performance this year from both the Companion Animal and Farm Animal segments, and a strong showing from H1 24 in profitability, we have revised upwards our 2024 earnings ..."

Pages
53
Language
English
Published on
01/10/24
You may also be interested by these reports :
10/10/24
GSK agreeing to settle c.93% of Zantac cases for $2.3bn has been well-received by investors, as the figure was lower than the market’s estimate, ...

09/10/24
As a consequence of the upward revision in our earnings estimates, the DCF and the NAV, the overall target price resets some c.13% higher. While we ...

08/10/24
Lundbeck has been surpassing expectations this year, backed by the healthy performances of its four key brands; this has prompted us to revise our ...

01/10/24
Considering the robust performance this year from both the Companion Animal and Farm Animal segments, and a strong showing from H1 24 in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO